Overview of Systematic Reviews on Shuxuetong Injection for Ischemic Stroke

An overview of 16 systematic reviews on Shuxuetong injection for ischemic stroke, published by Yifan Zhu in 2026. The document synthesizes evidence from Chinese and English databases up to January 2025, evaluating methodological quality, reporting, risk of bias, and certainty of evidence. It includes assessments using AMSTAR-2, PRISMA 2020, ROBIS, and GRADE tools.

Use Cases

• Assessing methodological quality of systematic reviews based on AMSTAR-2 and PRISMA 2020 scores
• Evaluating the certainty of evidence for clinical outcomes based on GRADE assessments
• Analyzing overlap in primary studies across multiple systematic reviews
• Critically appraising the risk of bias in systematic reviews using the ROBIS tool

Strengths

• Includes 16 systematic reviews with quantitative overlap assessment
• Evaluates 125 outcomes with GRADE certainty ratings (7 moderate, 21 low, 97 very low)
• Uses four established methodological assessment tools (AMSTAR-2, PRISMA 2020, ROBIS, GRADE)
• Pre-registered protocol on PROSPERO (CRD42025638286)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The underlying systematic reviews were assessed as having critically low confidence and high risk of bias

Provenance

Source

Yifan Zhu via figshare

Collection Method

Systematic searches across eight Chinese and English databases, with independent screening and data extraction by reviewers.

Time Range

From database inception to 25 January 2025

Freshness

Last updated 2026-04-13 05:45:55; freshness should be verified

Geography

Focus on studies from Chinese and English databases; specific geographic coverage of primary studies is not detailed.